A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety and effectiveness of a high dose of ABT-378/ritonavir

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abbott
• Treatments: HIV Protease Inhibitors; Lopinavir; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir

Criteria

Inclusion:

• HIV positive

• Are at least 18 years old

• Subject has not been treated for an active AIDS-defining opportunistic infection within 15 days of screening

• HIV RNA level > 1000 copies/mL

• Previous therapy with at least one protease inhibitor, at least one non-nucleoside reverse transcriptase inhibitor and at least one nucleoside reverse transcriptase inhibitor

Exclusion:

• Subject is pregnant or breast-feeding

• Subject has received an investigational drug within 30 days prior to screening

• Have a history of pancreatitis

• History of intolerance to ritonavir

• Abnormal laboratory tests at screening